For those of you expecting us to pay homage to Usain Bolt, we apologize, but we've moved on. As Beijing passed the torch to London, we bid zai jian to the Bird's Nest, the Cube, and the smog, and say 'ello luv to pub food, double decker buses, and East Enders. And we're pretty sure famed Leona Lewis didn't lip sync her version of 'Whole Lotta Love'.
Meantime Americans were treated to a new phase in a longer and potentially more grueling event than the decathlon--the 2008 election. The Dems finally have a ticket as the party convention gets underway in Denver this week.
But what about the wide world of health care?
- The auction for Elan's drug delivery technologies business continues apace, with Ireland's Sunday Times reporting that Warburg Pincus has entered the fray, joining other private equity players like TPG and Bain Capital (via Reuters).
MGIEisai and Helsinn Healthcare received approval for their oral formulation of the nausea and vomiting drug Aloxi over the weekend. The drug, used to treat nausea and vomiting associated with chemotherapy or surgery, is already available as an injection.
- Pfizer has discontinued testing of PF-03187207 for glaucoma in Asia after Phase II results of the NO-donating prostaglandin analog failed to impress. Ex-Asia development was similarly halted earlier this year based on Phase II results in the US. Partner NicOx said this morning that it was in discussions with Pfizer to regain the worldwide rights to the compound, which it felt still had "certain commercial potential which should be realized."